XOMA Corp (XOMA) Expected to Post Quarterly Sales of $2.95 Million
Wall Street brokerages forecast that XOMA Corp (NASDAQ:XOMA) will announce $2.95 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for XOMA’s earnings, with estimates ranging from $1.00 million to $4.90 million. XOMA posted sales of $36.18 million in the same quarter last year, which suggests a negative year over year growth rate of 91.8%. The firm is scheduled to announce its next quarterly earnings report on Monday, November 5th.
On average, analysts expect that XOMA will report full year sales of $9.75 million for the current financial year, with estimates ranging from $6.00 million to $13.50 million. For the next fiscal year, analysts forecast that the firm will report sales of $12.60 million per share, with estimates ranging from $6.00 million to $19.20 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow XOMA.
XOMA (NASDAQ:XOMA) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). XOMA had a net margin of 43.55% and a return on equity of 379.39%. The company had revenue of $2.26 million during the quarter, compared to analysts’ expectations of $4.57 million.
Shares of XOMA stock traded up $0.18 on Tuesday, hitting $16.50. The stock had a trading volume of 1,474 shares, compared to its average volume of 85,912. The company has a debt-to-equity ratio of 3.06, a quick ratio of 12.46 and a current ratio of 12.46. XOMA has a one year low of $15.35 and a one year high of $37.25. The stock has a market capitalization of $140.07 million, a price-to-earnings ratio of 16.65 and a beta of 2.46.
Large investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new stake in shares of XOMA during the 1st quarter valued at $243,000. Allianz Asset Management GmbH raised its holdings in shares of XOMA by 32.7% in the 1st quarter. Allianz Asset Management GmbH now owns 12,245 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 3,020 shares during the period. Tibra Equities Europe Ltd purchased a new stake in shares of XOMA in the 1st quarter valued at $283,000. ClariVest Asset Management LLC purchased a new stake in shares of XOMA in the 1st quarter valued at $380,000. Finally, Alps Advisors Inc. raised its holdings in shares of XOMA by 82.6% in the 2nd quarter. Alps Advisors Inc. now owns 19,946 shares of the biotechnology company’s stock valued at $542,000 after buying an additional 9,024 shares during the period. Institutional investors and hedge funds own 43.60% of the company’s stock.
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
Further Reading: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.